Abbott LaboratoriesvsRoyalty Pharma

ABT and RPRX stock compared: price, dividend, valuation and results, from SEC filings.

ABT

Abbott Laboratories

$104.48

Value $182B

-0.22%
ABT's page

Abbott Laboratories (ABT) has a market value of $182B and Royalty Pharma (RPRX) $29.5B. Over the last year, with dividends, ABT moved -17.7% and RPRX +78.4%. The P/E is 38.6 for ABT and 43.9 for RPRX. Dividend yield: ABT 2.41%, RPRX 1.37%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABT$182B

    RPRX$29.5B

    ABT is 6.2 times RPRX

  • Revenue, 12 months

    ABT$48.2B

    RPRX$2.6B

    ABT is 18 times RPRX

  • Net income, 12 months

    ABT$4.7B

    RPRX$672M

    ABT is 7.0 times RPRX

  • Operating margin

    ABT13.8%

    RPRX57.1%

    43.3 points apart

  • ROIC

    ABT6.3%

    RPRX6.3%

    About the same

  • P/E

    ABT38.6

    RPRX43.9

    RPRX is 1.1 times ABT

  • Dividend yield

    ABT2.4%

    RPRX1.4%

    1.0 points apart

  • 5-year return

    ABT-10.3%

    RPRX+82.2%

    92.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABT-10.3%

RPRX+82.2%

10015020222023202420252026
Returns by period
PeriodABTWith dividendsRPRXWith dividends
1 year since November 17, 2025-17.7%Price -19.6%+78.4%Price +75.4%
3 years since November 17, 2023+11.8%+3.8% a yearPrice +5.0%+177.4%+40.5% a yearPrice +158.2%
5 years since November 17, 2021-10.3%-2.1% a yearPrice -18.8%+82.2%+12.8% a yearPrice +61.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABTAbbott LaboratoriesRPRXRoyalty Pharma

Valuation

ABTRPRX
Valuation
Price$104.48$68.67
Market value$182B$29.5B
Enterprise value (EV)$208B$37.6B
P/E38.643.9
P/E, 5-year median33.717.5
P/B3.63.0
EV/EBIT31.425.1
Free cash flow yield3.7%10.0%

Results and growth

ABTRPRX
Results and growth
Revenue, 12 months$48.2B$2.6B
Net income, 12 months$4.7B$672M
Free cash flow, 12 months$6.8B$3.0B
Earnings per share, 12 months$2.69$1.53
Revenue growth, year on year5.7%5.1%
Revenue growth a year, past+5.1%over 5 years+2.3%over 5 years
EPS growth a year, past+8.3%over 5 years+6.2%over 5 years

Margins and returns on capital

ABTRPRX
Margins and returns on capital
Gross margin56.9%–
Operating margin13.8%57.1%
Net margin9.8%25.7%
ROIC6.3%6.3%
ROE9.1%6.9%

Balance sheet

ABTRPRX
Balance sheet
Cash$4.3B$545M
Total debt$31.2B$8.6B
Net debt / EBITDA3.35.4
Interest cover6.7×4.0×

Dividends and buybacks

ABTRPRX
Dividends and buybacks
Dividend yield2.4%1.4%
Dividend per share, 12 months$2.52$0.94
Dividend growth a year, past+10.4%over 5 years–
Buyback yield0.5%4.2%
Shareholder yield2.9%5.5%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABT or RPRX

Didn't find what you were looking for?

Ask us
Which is bigger, Abbott Laboratories or Royalty Pharma?

By market value, Abbott Laboratories ($182B) is about 6.2 times Royalty Pharma ($29.5B), at today's prices.

How did ABT and RPRX stock do over the last 5 years?

Since November 17, 2021, ABT's price moved -18.8% and RPRX's +61.7%. With dividends: ABT -10.3% (-2.1% a year), RPRX +82.2% (+12.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABT or RPRX?

The dividend yield at today's price is 2.41% for Abbott Laboratories and 1.37% for Royalty Pharma. Over the last twelve months they paid $2.52 and $0.94 per share.

What is the P/E of ABT and RPRX?

At today's price, the P/E is 38.6 for ABT and 43.9 for RPRX. The median of the last five years was 33.7 and 17.5, which shows where each stands against its own past.

Which has the higher profit margins, Abbott Laboratories or Royalty Pharma?

Over the last twelve months, the net margin was 9.8% for Abbott Laboratories and 25.7% for Royalty Pharma, and the operating margin 13.8% and 57.1%. Revenue was $48.2B and $2.6B.

Which is the better investment, Abbott Laboratories or Royalty Pharma?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.